P21
$63.99 – $79.99Price range: $63.99 through $79.99
A tetrapeptide mimetic of ciliary neurotrophic factor (CNTF) with an adamantane C-terminal modification, designed to cross the blood-brain barrier and promote neurogenesis.
Molecular & analytical data
Verified chemistry and third-party reference identifiers for this compound.
Reconstitution calculator
Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →
—
A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.
Quality & verification
Every batch is characterised before release and ships with documentation.
Storage & handling
Keep the peptide stable from delivery through reconstitution.
Lyophilized: room temperature; reconstituted: −20°C; nasal spray solutions: refrigerate 2–8°C
P21 (also written P021) is a synthetic tetrapeptide derived from the most bioactive region of ciliary neurotrophic factor (CNTF), specifically residues 148–151, modified with an adamantylated glycine at the C-terminus. This dual modification—adamantane group and N-terminal acetylation—dramatically improves blood-brain barrier (BBB) penetration by reducing polarity and resistance to exopeptidase degradation, allowing intranasal or subcutaneous administration with central nervous system delivery. CNTF naturally promotes neuron survival, neurite outgrowth, and neurogenesis, but its full-length protein cannot cross the BBB effectively. P21 retains the core neurotrophic signaling capability by acting on JAK/STAT and MAPK/ERK pathways via the CNTF receptor complex. Preclinical studies demonstrate that P21 increases adult hippocampal neurogenesis, improves spatial memory in cognitively impaired rodents, and shows benefits in models of Alzheimer’s disease by reducing tau phosphorylation and amyloid burden. Research in CDKL5 deficiency disorder models has also shown promise. P21 is investigated as a nootropic and neuroprotective agent.
Certificates of Analysis
Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.
| Batch # | Issued | Purity | Certificate |
|---|---|---|---|
| NHV26-P8196 COA-VXQ0-4F0W-M | 04 Aug 2026 | 99.06 % HPLC | Verify at IRZC ↗ |
“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.
The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.
Mechanism of action
In published preclinical work P021 acts by competitively inhibiting leukemia inhibitory factor (LIF) signalling — a negative regulator of neurogenesis — rather than by agonising the CNTF receptor complex; it increases BDNF expression, reported to act through TrkB–PI3K–AKT signalling with downstream inhibition of GSK-3β; promotes hippocampal neurogenesis, neurite outgrowth and synaptic plasticity; reduces tau hyperphosphorylation; crosses the BBB via adamantane-mediated lipophilicity.
Primary uses / indications
Cognitive decline; neurogenesis support; Alzheimer's disease (preclinical); CDKL5 deficiency disorder (preclinical); nootropic use; neuroprotection after CNS injury
Typical dosage (reported)
200–400 mcg/day intranasal (research protocols)
Cycle duration (reported)
4–8 weeks typical research cycle
Administration route
Intranasal spray (primary research route); subcutaneous injection
Side effects (reported)
Generally well tolerated in animal studies; limited human safety data; potential headache; unknown long-term effects
Contraindications
Limited human data; pregnancy and lactation (avoid); concurrent SSRI/SNRI (theoretical interaction)
Drug interactions
Potential interactions with JAK inhibitors; additive neurogenic effects with Semax; theoretical serotonergic interaction
Identity
| Full name / brand names | P21; P021; CNTF Peptide Mimetic; Neurogenesis Peptide |
|---|---|
| Category | Cognitive & Neuroprotective |
| Subcategory | Neurogenesis Peptide |
| Origin / source | Synthetic; derived from CNTF sequence (Genebank/UniProt); developed by researchers at New York State Institute for Basic Research |
| Year discovered | 2010s (development as CNTF mimetic) |
Chemistry
| Amino acid sequence | Ac-Asp-Gly-Gly-Leu-(adamantyl)Gly-NH2 — published as Ac-DGGL(A)G-NH2: a DGGL core with a C-terminal adamantylated glycine |
|---|---|
| Molecular formula | C27H42N6O8 |
| Molecular weight | 578.66 g/mol |
| CAS number | 1246751-68-7 |
| Purity standard | ≥98% |
Pharmacokinetics
| Half-life | ~2–4 hours (estimated based on peptide degradation) |
|---|---|
| Bioavailability | CNS delivery via intranasal route; subcutaneous bioavailability not fully characterized |
Regulatory & research status
| FDA status | Not FDA approved; research compound |
|---|---|
| Prescription required | No (research use only) |
| Research status | Preclinical (animal studies); early research phase |
| Clinical trials | No registered clinical trials as of 2026 |
References
1. Kazim SF, Blanchard J, Dai CL, et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2014;71:110-130. PMID 25046994. 2. Mottolese N, Loi M, Trazzi S, et al. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. J Neurodev Disord. 2024;16(1):65. doi:10.1186/s11689-024-09583-4.
Frequently asked questions
What is P21?
How does P21 work?
What P21 dosage is used in research?
What is the half-life of P21?
How should P21 be stored and reconstituted?
What purity is NHOV's P21?
Is P21 approved for human use?
Related products
Selank
Synthetic heptapeptide analog of tuftsin; GABAergic and BDNF research.
$28.99 – $43.99Price range: $28.99 through $43.99
Pre-order Cerebrolysin
Porcine brain-derived neuropeptide digest; studied in neurotrophic research.
$34.99 – $54.99Price range: $34.99 through $54.99PE-22-28
Synthetic spadin analog and TREK-1 potassium channel blocker; neurotropic research.
$26.99 – $49.99Price range: $26.99 through $49.99Pinealon
Glu-Asp-Arg bioregulatory tripeptide studied in circadian and CNS research.
$34.99 – $45.99Price range: $34.99 through $45.99
N-Acetyl Selank Amidate
TKPRPGP analog with acetylated and amidated termini blocking peptidase cleavage.
$20.99 – $33.99Price range: $20.99 through $33.99MIF-1
Oxytocin-derived tripeptide; allosteric modulator of D2/D4 dopamine receptors.
$34.99 – $54.99Price range: $34.99 through $54.99
CerebroNeurogen
Porcine brain-derived peptide hydrolysate studied in neuroprotection research.
$34.99 – $54.99Price range: $34.99 through $54.99Dermorphin
Naturally occurring frog-skin heptapeptide; selective mu-opioid receptor agonist.
$79.99 – $127.99Price range: $79.99 through $127.99







Reviews
Clear filtersThere are no reviews yet.